Street Calls of the Week
Investing.com - H.C. Wainwright has maintained its Buy rating and $7.00 price target on Enlivex Therapeutics (NASDAQ:ENLV), according to a research note released Monday. The target represents significant upside potential from the current price of $1.07, with analyst targets ranging from $7.00 to $13.00. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 6.41.
The research firm highlighted BPL-003 as the lead value driver for the company, noting its rapid onset, eight-week durability, and scalability within the two-hour interventional psychiatry framework.
In a separate development on September 8, H.C. Wainwright hosted atai Life Sciences management, including CEO Srinivas Rao, during the firm’s 27th Annual Global Investment Conference.
During this conference, atai’s management emphasized the company’s leadership in short-acting psychedelics, highlighting both clinical data and program scalability, particularly for BPL-003 (intranasal mebufotenin, or 5-MeO-DMT).
H.C. Wainwright also maintains a Buy rating and $15 price target on atai Life Sciences, viewing the company as well-positioned amid renewed strategic interest in psychedelics for psychiatric applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.